FPH reports strong revenue and profit growth for FY26
Fisher & Paykel Healthcare reported FY26 results for the year ended 31 March 2026: operating revenue rose 14% to $2.31 billion (12% constant currency) and net profit after tax increased 24% to $468.5 million (28% constant currency). Hospital revenue grew 18% to $1.51 billion; Homecare revenue rose 8% to $802.7 million. Gross margin improved to 63.7%. The board set a final dividend of 33.0 cents per share. Outlook for FY27: revenue $2.45–$2.57 billion and profit $500–$550 million.
How this was made
The 30-second read
Why it matters
The combination of strong FY26 financials, improved gross margin, and a higher dividend increases confidence in earnings quality; however, FY27 guidance includes margin drag assumptions from US tariffs and the Middle East conflict.
Market read
Results and guidance are likely to drive trading as they confirm growth across Hospital and Homecare, with margin improvement partially offset by tariff/geopolitical headwinds.
What to watch
Hospital admissions were described as subdued yet consumables grew—investors may scrutinize whether growth is sustainable versus catch-up from prior-year seasonality.
Background
Fisher & Paykel Healthcare (respiratory care, surgery, and OSA homecare) released full-year FY26 results and FY27 outlook, including tariff and geopolitical margin effects.
Ticker impact
Fisher & Paykel Healthcare reported FY26 operating revenue +14% and net profit after tax +24%, plus FY27 revenue/profit guidance.
Likely positive reaction as results and guidance confirm growth and margin trajectory; volatility possible around tariff/margin assumptions.
The article provides both realized growth (revenue/profit/margins) and explicit FY27 ranges, including quantified gross-margin impacts from tariffs and the Middle East conflict.
Market effects
Read-through to medical device/respiratory and homecare consumables demand; consumables growth suggests resilient utilization and clinical adoption.
NZ-listed healthcare name may see cross-market flows tied to USD/EUR/MXN FX sensitivity and tariff exposure.
US tariff and Middle East conflict margin assumptions highlight global supply-chain and demand sensitivity for respiratory/hospital products.
Counterpoint
Tariff and conflict-related gross-margin impacts are explicitly embedded in FY27 outlook, so upside may be capped if macro conditions worsen.
Key entities
- companyFisher & Paykel Healthcare
Reported FY26 revenue/profit growth, improved gross margin, and provided FY27 revenue/profit guidance and dividend details.
